Radiopharmaceutical developer Cerveau Technologies announced a licensing agreement with biotechnology company Alector for use of its MK-6240 investigational tau imaging agent for PET scans.
The radiopharmaceutical will be used in PET scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer's disease, according to Cerveau.
The collaboration will use MK-6240 as an exploratory biomarker in studies on neurodegenerative disease research conducted by Alector. The companies will collaborate to evaluate the effect of therapies on the progression of neurodegenerative diseases.
